Widely used:Recently Viewed
Clear AllQuality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$13 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-2 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
9
Industry P/E
--
EV/EBITDA
-0
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-67.3
Face value
--
Shares outstanding
1,645,450
CFO
$-40.48 Mln
EBITDA
$7.02 Mln
Net Profit
$-25.94 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Portage Biotech (PRTG)
| 46.0 | -15.0 | 60.5 | 44.6 | -60.7 | -50.3 | -16.0 |
|
BSE Sensex*
| 5.2 | 7.3 | 8.4 | 12.8 | 16.0 | 21.5 | 11.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
|---|---|---|
|
Portage Biotech (PRTG)
| -65.6 | -50.7 |
|
S&P Small-Cap 600
| 13.9 | -17.4 |
|
BSE Sensex
| 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Portage Biotech (PRTG)
|
7.6 | 12.6 | 0.0 | -67.3 | -- | -2481.1 | -- | 9.0 |
| 15.8 | 2,007.5 | 0.0 | -846.4 | -- | -198.8 | -- | 7.7 |
Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline comprises PORT-8, a dual inhibitor of adenosine receptors 2A and 2B, which is in... preclinical trial to treat solid tumors; PORT-9, an A2B antagonist, which is in pre-clinical stage program to treat colorectal and gastrointestinal cancers; and PORT-3, a polylactide-co-glycolide, which is in phase 1 to treat NY-ESO-1 positive tumors. The company also develops PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors and is in preclinical trials. Portage Biotech Inc. is based in Tortola, British Virgin Islands. Address: Clarence Thomas Building, Tortola, British Virgin Islands, VG1110 Read more
CEO & Chairman of Board
Dr. Ian B. Walters M.B.A., M.D.
CEO & Chairman of Board
Dr. Ian B. Walters M.B.A., M.D.
Headquarters
Tortola
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Portage Biotech Inc (PRTG) stood at $ 4 Mln as on 30-Sep-24
The share price of Portage Biotech Inc (PRTG) is $7.55 (NASDAQ) as of 15-May-2025 16:21 EDT. Portage Biotech Inc (PRTG) has given a return of -60.66% in the last 3 years.
Portage Biotech Inc (PRTG) has a market capitalisation of $ 13 Mln as on 15-May-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Portage Biotech Inc (PRTG) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Portage Biotech Inc (PRTG) and enter the required number of quantities and click on buy to purchase the shares of Portage Biotech Inc (PRTG).
Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline comprises PORT-8, a dual inhibitor of adenosine receptors 2A and 2B, which is in preclinical trial to treat solid tumors; PORT-9, an A2B antagonist, which is in pre-clinical stage program to treat colorectal and gastrointestinal cancers; and PORT-3, a polylactide-co-glycolide, which is in phase 1 to treat NY-ESO-1 positive tumors. The company also develops PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors and is in preclinical trials. Portage Biotech Inc. is based in Tortola, British Virgin Islands. Address: Clarence Thomas Building, Tortola, British Virgin Islands, VG1110
The CEO & director of Dr. Ian B. Walters M.B.A., M.D.. is Portage Biotech Inc (PRTG), and CFO & Sr. VP is Dr. Ian B. Walters M.B.A., M.D..
There is no promoter pledging in Portage Biotech Inc (PRTG).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
433
|
| Portage Biotech Inc. (PRTG) | Ratios |
|---|---|
|
Return on equity(%)
|
-2481.14
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Portage Biotech Inc (PRTG) was $0 Mln.
$-0.13
(
